Envestnet Asset Management Inc. Sells 5,168 Shares of DaVita Inc. $DVA

Envestnet Asset Management Inc. cut its stake in shares of DaVita Inc. (NYSE:DVA) by 32.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,981 shares of the company’s stock after selling 5,168 shares during the quarter. Envestnet Asset Management Inc.’s holdings in DaVita were worth $1,459,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in DVA. Hantz Financial Services Inc. lifted its holdings in DaVita by 341.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,020 shares of the company’s stock valued at $136,000 after purchasing an additional 789 shares during the last quarter. Jones Financial Companies Lllp raised its stake in shares of DaVita by 57.1% in the third quarter. Jones Financial Companies Lllp now owns 1,508 shares of the company’s stock valued at $197,000 after acquiring an additional 548 shares during the last quarter. State of Wyoming boosted its holdings in shares of DaVita by 6.1% in the 3rd quarter. State of Wyoming now owns 2,928 shares of the company’s stock worth $389,000 after acquiring an additional 169 shares in the last quarter. Mediolanum International Funds Ltd grew its position in DaVita by 57.3% during the 3rd quarter. Mediolanum International Funds Ltd now owns 10,840 shares of the company’s stock worth $1,416,000 after acquiring an additional 3,950 shares during the last quarter. Finally, Financial Strategies Group Inc. raised its position in DaVita by 29.1% in the 3rd quarter. Financial Strategies Group Inc. now owns 7,046 shares of the company’s stock valued at $936,000 after purchasing an additional 1,590 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Performance

Shares of DVA stock opened at $156.28 on Monday. The firm’s 50 day moving average price is $124.18 and its two-hundred day moving average price is $125.91. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $157.91. The stock has a market cap of $10.44 billion, a PE ratio of 15.77, a PEG ratio of 0.55 and a beta of 0.93.

DaVita (NYSE:DVA) last issued its earnings results on Monday, February 2nd. The company reported $3.40 EPS for the quarter, beating the consensus estimate of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The company had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter in the previous year, the company posted $2.24 EPS. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, sell-side analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. TD Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Truist Financial set a $158.00 price target on shares of DaVita in a report on Thursday, February 5th. Finally, Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, DaVita has a consensus rating of “Hold” and an average price target of $155.80.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.